As of Thursday close, Allogene Therapeutics Inc.’s (NASDAQ:ALLO) stock was up $0.19, moving up 2.80 percent to $6.97. The average number of shares traded per day over the past five days has been 2,631,220 shares. 1 time new highs have been achieved over the past 5 days, with a -$2.28 fall in that time frame. In the last twenty days, the average volume was 2,143,080, while in the previous 50 days, it was 1,837,472.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .
Since last month, ALLO stock retreated -18.10%. Shares of the company fell to $6.43 on 05/12/22, the lowest level in the past month. A 52-week high of $31.77 was reached on 01/03/22 after having rallying from a 52-week low of $6.73. Since the beginning of this year, ALLO’s stock price has dropped by -53.28% or -$7.95, and marked a new high 1 time. However, the stock has declined by -78.06% since its 52-week high.
Allogene Therapeutics Inc. (ALLO) last reported insider trading activity 59 days ago on Mar 15. Amado Rafael, the EVP of R&D and CMO of the company, disposed of 5,169 shares for $7.71 on Mar 15. It resulted in a $39,848 divestment by the insider. MOORE ALISON sold 8,698 shares at an average price of $7.63 on Mar 15. The insider now owns 120,430 shares following the transaction. On Mar 15, Chief Financial Officer SCHMIDT ERIC THOMAS sold 11,469 shares at $7.63 apiece. The transaction was valued at $87,551.
The stock’s beta is 0.87. Besides these, the trailing price-to-sales (P/S) ratio of 5042.45, the price-to-book (PB) ratio of 1.15.
In the three months ended September 29, Allogene Therapeutics Inc.’s quick ratio stood at 12.70, while its current ratio was 12.70, showing that the company is able to pay off its debt. Based on annual data, ALLO earned $294.28 million in gross profit and brought in $38.49 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -27.90%. Return on equity (ROE) for the past 12 months was -32.30%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. ALLO’s revenue fell -63816.67% during the quarter, while net income inched up to $60000.0. While analysts expected Allogene Therapeutics Inc. to report -$0.56 quarterly earnings, the actual figure was -$0.57 per share, beating the consensus estimate by -1.80%. During the quarter, the company generated -$74.97 million in EBITDA. The liabilities of Allogene Therapeutics Inc. were 109.4 million at the end of its most recent quarter ended September 29, and its total debt was $73.13 million. The value of shareholders’ equity is $143.6 million.
This quick technical analysis looks at Allogene Therapeutics Inc.’s (ALLO) price momentum. With a historical volatility rate of 143.90%, the RSI 9-day stood at 32.87% on 12 May.
With respect to its five-day moving average, the current Allogene Therapeutics Inc. price is down by -24.65% percent or -$2.28. At present, ALLO shares trade -20.43% below its 20-day simple moving average and -55.91% percent below its 100-day simple moving average. However, the stock is currently trading approximately -20.52% below its SMA50 and -69.12% below its SMA200.
Stochastic coefficient K was 12.19% and Stochastic coefficient D was 16.20%, while ATR was 0.81. Given the Stochastic reading of 14.71% for the 14-day period, the RSI (14) reading has been calculated as 36.34%. As of today, the MACD Oscillator reading stands at -1.17, while the 14-day reading stands at -1.20.
B. Riley Securities reiterated its a Buy rating on Allogene Therapeutics Inc. (NASDAQ: ALLO) in a note to investors. The analysts firm has however raised their price target to $21, representing a possible 76.77% increase in the stock price. Allogene Therapeutics Inc. (ALLO) has been rated Overweight by analysts. According to 0 brokerage firms, ALLO is a sell, and 4 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 1 analyst rate Allogene Therapeutics Inc. stock as buy, with 13 recommending it as overweight.
With a median target price of $23.50, the current consensus forecast for the stock is $12.00 – $55.00. Based on these forecasts, analysts predict Allogene Therapeutics Inc. (ALLO) will achieve an average price target of $26.81.